B6;D2-Tg(Egr2-lacZ)4Pch/Orl
| Status | Available to order |
| EMMA ID | EM:11832 |
| Citation information | RRID:IMSR_EM:11832 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6;D2-Tg(Egr2-lacZ)4Pch/Orl |
| Alternative name | MSE |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(Egr2-lacZ)4Pch |
| Gene/Transgene symbol | Tg(Egr2-lacZ)4Pch |
Information from provider
| Provider | Carole Desmarquet-Trin-Dinh |
| Provider affiliation | Equipe Developpement du Systeme Nerveux IBENS, INSERM U 1024, CNRS UMR 8197, Ecole Normale Superieure |
| Genetic information | Transgene: myelinating Schwann cell element (MSE) region from mice Egr2 (Krox20), driving lacZ expression (MSE transgenic) - Egr2: early growth response 2 gene. |
| Phenotypic information | Homozygous:Nothing to reportHeterozygous:Nothing to report |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | CNRS-TAAM – Typing and Archiving of Animal Models, Orléans, France |
| Animals used for archiving | heterozygous (C57BL/6 x DBA/2)F1 males, wild-type (C57BL/6 x DBA/2)F1 females |
| Stage of embryos | 2-cell |
Literature references
- Characterisation of cis-acting sequences reveals a biphasic, axon-dependent regulation of Krox20 during Schwann cell development.;Ghislain Julien, Desmarquet-Trin-Dinh Carole, Jaegle Martine, Meijer Dies, Charnay Patrick, Frain Monique, ;2002;Development (Cambridge, England);129;155-66; 11782409
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).
